PHGE
Tessera Defense and Homeland Security Inc.
Set alert
1.85 USD +0.23 +14.20%
1.65 Day range 2.16
0.48 52-week range 8.55
- YTD
- -1.07%
- 1 year
- -78.36%
- Open
- 1.66
- Prev close
- 1.62
- Mkt cap
- 10.00M
- Vol
- 3.27M
- Avg vol
- 87.78K
- EPS
- -3.26
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 1.65
- High
- 2.16
- Forward P/E
- 0.00
- Beta
- 1.32
- Short ratio
- 0.74
- Inst. own
- 52.31%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Aug 14, 2024
- 50-d avg
- 0.7297
- 200-d avg
- 2.23
- 1y target
- 7.00
Key statistics
- Market cap
- 10.00M
- Enterprise value
- 24.13M
- Trailing P/E
- 0.00
- Forward P/E
- 0.00
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.82
- EPS (TTM)
- -3.26
- Beta
- 1.32
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 0
- Revenue growth
- 0.00%
- Free cash flow
- -17.37M
- Total cash
- 31.61M
- Total debt
- 9.90M
- Return on equity
- -121.29%
- Shares outstanding
- 18.18M
- Short % of float
- 0.15%
- 50-day average
- 0.7297
- 200-day average
- 2.23
Analyst view
Consensus: none
Price target (mean) 7.00 +278.4% upside
Now 1.85
- Target (low)
- 2.00
- Target (mean)
- 7.00
- Target (high)
- 12.00
Ratings (0m) 2 2 buy · 0 hold · 0 sell
- Strong buy2
- Buy0
- Hold0
- Sell0
- Strong sell0
Next earnings
Aug 14, 2024
Expected Aug 14, 2024. Consensus EPS estimate -1.10.
Financials — quick view
PHGE Revenue — quarterly 332.00K
PHGE Net income — quarterly -3.77M
PHGE EPS — quarterly -3.70
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 14, 2024 | Sep 1, 2024 | -0.60 | -0.97 | -0.37 | -61.67% |
| Aug 14, 2024 | Jun 1, 2024 | -1.20 | 0.70 | +1.90 | +158.33% |
| Aug 14, 2024 | Jun 1, 2024 | -1.20 | — | — | — |
| May 20, 2024 | Mar 1, 2024 | -0.70 | — | — | — |
| May 20, 2024 | Mar 1, 2024 | -0.70 | -1.50 | -0.80 | -114.29% |
| Apr 3, 2024 | Dec 1, 2023 | 0.00 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Aug 16, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| May 28, 2024 | Laidlaw & Co. | init | — | Buy |
| May 21, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Apr 22, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Apr 3, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Mar 7, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
About Tessera Defense and Homeland Security Inc.
BiomX Inc., a clinical-stage biopharmaceutical company, develops products using natural and engineered phage technologies designed to target and kill specific harmful bacteria associated with chronic disease. It is developing BX211, a phage therapy, which is in phase 2 clinical study for the treatment of diabetic foot osteomyelitis. The company's product pipeline also includes BX004, a phage therapy for cystic fibrosis patients with chronic pulmonary infections caused by Pseudomonas aeruginosa that is in Phase 1b/2a clinical trials. BiomX Inc. was founded in 2015 and is headquartered in Ness Ziona, Israel.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- Israel
- Website
- biomx.com
News
- Tessera Defense and Homeland Security CEO Issues Letter to Shareholders
- BiomX: Zorronet Launches No-Code Control Over AI-Powered Autonomous Response Workflows
- BiomX Inc. to Become Tessera Defense and Homeland Security Inc.
- Stock Market Today: S&P 500, Nasdaq 100, Dow Jones Futures Fall as US-Iran Tensions Flare Up—WMT, RZLV, FNGR in Focus (UPDATED)
- SAIC, Walmart And 3 Stocks To Watch Heading Into Monday
- BiomX Subsidiary Zorronet Receives Approximately $300,000 Purchase Order to Build Unified Operational Environment at Defense Technology Test and Evaluation Site
- BiomX Acquires 10% Stake in Motomea, Inventor of Advanced Electric Motor Technologies for Drone and Autonomous Systems
- BiomX And Water.IO Agree To Updated Zorronet Acquisition Terms
- 12 Health Care Stocks Moving In Tuesday's Pre-Market Session
- BiomX Subsidiary Zorronet Expands European Presence Through Two Strategic Collaborations in Europe
Your note
Sign in to keep a note on PHGE — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BASSAN MARAV | Officer | Stock Award(Grant) | Sep 15, 2024 | 31,749 |
| CYSTIC FIBROSIS FOUNDATION | Beneficial Owner of more than 10% of a Class of Security | Conversion of Exercise of derivative security | May 14, 2024 | 9,330,580 |
| FLYNN JAMES E | Director | Conversion of Exercise of derivative security | Jul 14, 2024 | 0 |
| ORBIMED ISRAEL BIOFUND GP, L. P. | Beneficial Owner of more than 10% of a Class of Security | Sale | May 14, 2024 | 0 |
| ORON ASSAF | Officer | Stock Award(Grant) | Sep 15, 2024 | 25,804 |
| SOLOMON JONATHAN EITAN | Chief Executive Officer | Stock Award(Grant) | Sep 15, 2024 | 53,056 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Orbimed Advisors LLC. | 9.84% | 1,787,767 | 983.27K | Sep 29, 2024 |
| Deerfield Management Company, L.P. (Series C) | 9.83% | 1,787,610 | 983.18K | Sep 29, 2024 |
| Nantahala Capital Management, LLC | 9.52% | 1,730,600 | 951.83K | Sep 29, 2024 |
| Ikarian Capital, LLC | 4.91% | 893,000 | 491.15K | Sep 29, 2024 |
| AIGH Capital Management LLC | 4.76% | 865,400 | 475.97K | Sep 29, 2024 |
| Heights Capital Management, Inc | 3.24% | 589,027 | 323.96K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Bridgeway Funds Inc-Ultra Small Company Market Fund | 0.07% | 49,500 | 27.23K | Dec 30, 2023 |